Compare CHDN & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHDN | MIRM |
|---|---|---|
| Founded | 1928 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.7B |
| IPO Year | 1995 | 2019 |
| Metric | CHDN | MIRM |
|---|---|---|
| Price | $85.50 | $122.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | ★ $138.44 | $119.85 |
| AVG Volume (30 Days) | ★ 1.1M | 945.6K |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.43% | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ 5.49 | N/A |
| Revenue | ★ $1,809,800,000.00 | $19,138,000.00 |
| Revenue This Year | $5.75 | $26.22 |
| Revenue Next Year | $3.52 | $22.04 |
| P/E Ratio | $15.69 | ★ N/A |
| Revenue Growth | ★ 13.31 | N/A |
| 52 Week Low | $81.45 | $50.25 |
| 52 Week High | $118.46 | $130.00 |
| Indicator | CHDN | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 44.93 | 60.48 |
| Support Level | $84.10 | $88.92 |
| Resistance Level | $90.25 | N/A |
| Average True Range (ATR) | 3.26 | 6.48 |
| MACD | -0.24 | 0.71 |
| Stochastic Oscillator | 30.53 | 68.21 |
Churchill Downs Inc is a gaming entertainment, online wagering, and racing company. It operates through three business segments: Live and Historical Racing, Wagering Services, and Gaming. The Live and Historical Racing segment includes live and historical pari-mutuel racing. The Wagering Services segment includes the revenue and expenses from pari-mutuel wagers through TwinSpires, companies retail and online sports betting business and Gaming segment includes revenue and expenses for the casino properties and associated racetracks that support the casino license. The Gaming segment generates revenue and expenses from slot machines, video lottery terminals, video poker, HRMs, ancillary food and beverage services, hotel services, commission on pari-mutuel wagering, and racing events.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.